Despite the federal government’s rescheduling of medical cannabis, the implications for employment law remain unchanged, with workplace protections for patients still largely determined by state regulations rather than the new federal classification.
Understanding the Impact of Federal Rescheduling
On April 23, 2026, the Department of Justice reclassified cannabis associated with state medical marijuana licenses from Schedule I to Schedule III of the Controlled Substances Act, affecting products linked to state licenses and FDA-approved cannabis, while leaving recreational and unlicensed cannabis in Schedule I.
This rescheduling has eased restrictions on research, taxation, and interstate distribution for licensed operators, but it does not obligate employers to accommodate cannabis use or alter federally mandated drug testing programs, such as those administered by the Department of Transportation. A parallel hearing on broader rescheduling for recreational cannabis, which commenced on June 29, 2026, is ongoing, with its outcome pending.
The Role of State Law in Workplace Protections
As employment law is primarily a state concern, the regulations governing patients’ rights are rooted in their state’s cannabis statute, rather than federal scheduling decisions. Approximately half of the states with medical cannabis programs have incorporated anti-discrimination provisions for registered patients, according to the National Conference of State Legislatures.
States like California and Connecticut prohibit employers from disciplining workers solely based on a positive THC test resulting from lawful off-duty use, whereas states such as Colorado grant employers broader authority to enforce zero-tolerance policies, regardless of a patient’s medical status. Consequently, workers’ protections can vary significantly depending on the state in which they are employed.
Read Also: Companies focus on resilience over compliance
Most state protections apply exclusively to patients with valid, current documentation, rather than to cannabis users in general. Patients who have undergone a licensed telehealth evaluation to obtain a recommendation possess documented, state-recognized justification for their cannabis use, which is often required as evidence for employment protection statutes to apply. In contrast, patients without such documentation, even those using cannabis for legitimate health conditions, typically cannot claim the same protections.
Key Areas of Conflict Between Patients and Employers
Standard urine tests can detect THC metabolites long after any impairment has subsided, allowing a patient who used cannabis medically days earlier to still test positive at work. Many state laws differentiate between a positive test and actual on-the-job impairment, with some requiring employers to demonstrate impairment before taking action. However, the burden of proof and who bears it varies substantially from state to state.
Positions subject to federal safety regulations, including commercial driving and aviation, generally remain bound by zero-tolerance cannabis policies, as confirmed by the Department of Transportation’s ODAPC guidance, which has not changed following federal rescheduling. Employers in industries with federal contracts or funding also retain the right to enforce drug-free workplace policies as a condition of that funding. Patients working in these fields should assume state protections do not apply unless a federal agency indicates otherwise.
Practical Measures for Patients
Patient should familiarize themselves with their state’s cannabis and employment laws, rather than assuming workplace protections exist simply because medical cannabis is legal. State health department websites can provide up-to-date, plain-language guidance, often more current than private resources.
Patient should document any suspected discrimination related to their medical cannabis patient status, including dates, conversations, and supporting evidence, as soon as possible. Consulting an employment attorney before resigning, disclosing their patient status to HR, or accepting a settlement is advisable, particularly given the evolving nature of cannabis employment laws in 2026.
